Travere Therapeutics, Inc.
TVTX · Pharmaceutical Preparations · 93.0M shares · +15%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: -$42M (gross $2M, SBC $44M)
Reference price $50.00 · est. market cap ~$4.6B — last insider sale, 2026-06-12 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
C58Rare-kidney-disease company with a fast-growing approved IgAN drug but a failed FSGS confirmatory endpoint and continued losses.
Strengths
- Revenue +110% (85th pct), gross margin 98% (95th pct), ROA in 81st pct — strong commercial trajectory for FILSPARI
- PROTECT IgAN Phase 3 clearly positive (proteinuria and eGFR slope); full approval and Orphan exclusivity
- Solid cash ($322M, 78th pct) and milestone inflows
Risks
- DUPLEX FSGS missed its confirmatory eGFR slope endpoint (p=0.75) — sNDA hinges on surrogate; binary April 2026 PDUFA risk
- Still net-loss-making (net income growth 10th pct) with HCU manufacturing/enrollment setbacks
- Generic Thiola erosion and reliance on a single growth driver
Notable findings
- Chronic dilutionShare count +15%/yr over 4y (dilution, book value/share -78%)
- Net lossNet loss (net margin -5.2%)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Trial resultPositive trial readout — primary endpoint met (8-K) 8-K ↗
- Strong balance sheetStrong balance sheet — $323M cash & investments
- Insider sellingInsider selling — 63 open-market sale(s) by 11 insider(s) (cluster of 11 insiders, ~$26M, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2026-06 — PHASE1/PHASE2 · Homocystinuria
- Notable holderHeld by 5 notable fund(s): FMR LLC, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
97.9%
Operating margin
-12.8%
Net margin
-5.2%
Return on equity
-22.2%
Return on assets
-4.2%
Revenue growth (QoQ)
-1.9%
Current ratio
2.7×
EBITDA
-$2M
Tangible book value
$960K
Cash & investments
$323M
Stock comp / revenue
9.1%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-22 | Inrig Jula | Gift | 468 | — |
| 2026-06-12 | Baynes Roy D. | Option exercise | 4.5K | $21.38 |
| 2026-06-12 | Coughlin Timothy | Option exercise | 10K | $26.52 |
| 2026-06-12 | Coughlin Timothy | Sell | 10K | $50.07 |
| 2026-06-12 | Baynes Roy D. | Sell | 4.5K | $50.00 |
| 2026-05-19 | Coughlin Timothy | Grant | 4.0K | — |
| 2026-05-19 | Baynes Roy D. | Grant | 4.0K | — |
| 2026-05-19 | Poole Sandra | Grant | 4.0K | — |
| 2026-05-19 | Bruhn Suzanne Louise | Grant | 4.0K | — |
| 2026-05-19 | Meckler Jeffrey A | Grant | 4.0K | — |
| 2026-05-19 | Orwin John A | Grant | 4.0K | — |
| 2026-05-19 | Squarer Ron | Grant | 4.0K | — |
| 2026-05-19 | Williams Brinkley Ruth | Grant | 4.0K | — |
| 2026-05-19 | LYONS GARY A | Grant | 4.0K | — |
| 2026-05-15 | Coughlin Timothy | Sell | 3.2K | $43.49 |
| 2026-05-06 | REED ELIZABETH E | Sell | 2.1K | $43.95 |
| 2026-05-06 | Dube Eric M | Sell | 22K | $43.95 |
| 2026-05-06 | ROTE WILLIAM E. | Sell | 2.8K | $43.95 |
| 2026-05-06 | Cline Christopher R. | Sell | 310 | $43.95 |
| 2026-05-06 | Inrig Jula | Sell | 311 | $43.95 |
| 2026-05-05 | Heerma Peter | Sell | 2.2K | $46.65 |
| 2026-05-05 | Cline Christopher R. | Sell | 2.2K | $46.65 |
| 2026-05-05 | Baynes Roy D. | Sell | 4.5K | $46.65 |
| 2026-05-05 | REED ELIZABETH E | Sell | 2.2K | $46.65 |
| 2026-05-05 | Baynes Roy D. | Option exercise | 4.5K | $18.27 |
| 2026-05-05 | Inrig Jula | Sell | 2.2K | $46.65 |
| 2026-05-04 | REED ELIZABETH E | Option exercise | 20K | $17.96 |
| 2026-05-04 | Cline Christopher R. | Option exercise | 4.2K | — |
| 2026-05-04 | Inrig Jula | Option exercise | 20K | $22.40 |
| 2026-05-04 | Inrig Jula | Sell | 20K | $45.00 |
| 2026-05-04 | Inrig Jula | Option exercise | 4.2K | — |
| 2026-05-04 | Heerma Peter | Option exercise | 4.2K | — |
| 2026-05-04 | Dube Eric M | Option exercise | 22K | — |
| 2026-05-04 | ROTE WILLIAM E. | Option exercise | 4.2K | — |
| 2026-05-04 | Meckler Jeffrey A | Option exercise | 8.0K | $16.33 |
| 2026-05-04 | Meckler Jeffrey A | Sell | 8.0K | $45.00 |
| 2026-05-04 | REED ELIZABETH E | Sell | 20K | $45.00 |
| 2026-05-04 | REED ELIZABETH E | Option exercise | 4.2K | — |
| 2026-05-01 | Baynes Roy D. | Sell | 9.8K | $44.22 |
| 2026-05-01 | Baynes Roy D. | Option exercise | 9.8K | $6.82 |
| 2026-04-22 | ROTE WILLIAM E. | Sell | 9.1K | $39.09 |
| 2026-04-15 | Cline Christopher R. | Sell | 1.0K | $42.61 |
| 2026-04-15 | Inrig Jula | Sell | 1.0K | $42.61 |
| 2026-04-15 | Dube Eric M | Sell | 57K | $41.01 |
| 2026-04-15 | Dube Eric M | Sell | 7.2K | $41.75 |
| 2026-04-15 | Dube Eric M | Sell | 20 | $42.66 |
| 2026-04-15 | REED ELIZABETH E | Sell | 5.2K | $41.62 |
| 2026-04-15 | REED ELIZABETH E | Sell | 1.6K | $42.53 |
| 2026-04-14 | Baynes Roy D. | Sell | 6.8K | $42.12 |
| 2026-04-14 | LYONS GARY A | Option exercise | 8.0K | $16.33 |
| 2026-04-14 | REED ELIZABETH E | Option exercise | 10K | $19.08 |
| 2026-04-14 | REED ELIZABETH E | Option exercise | 20K | $17.96 |
| 2026-04-14 | REED ELIZABETH E | Option exercise | 7.5K | $15.46 |
| 2026-04-14 | REED ELIZABETH E | Sell | 38K | $41.07 |
| 2026-04-14 | REED ELIZABETH E | Sell | 7.2K | $41.93 |
| 2026-04-14 | LYONS GARY A | Sell | 8.0K | $41.07 |
| 2026-04-14 | Baynes Roy D. | Option exercise | 4.5K | $18.27 |
| 2026-04-14 | Baynes Roy D. | Option exercise | 4.5K | $21.38 |
| 2026-04-14 | Cline Christopher R. | Sell | 9 | $41.07 |
| 2026-04-14 | Cline Christopher R. | Sell | 7.2K | $41.93 |
| 2026-04-14 | Baynes Roy D. | Option exercise | 8.0K | $17.94 |
| 2026-04-14 | Baynes Roy D. | Option exercise | 6.8K | $17.11 |
| 2026-04-14 | Inrig Jula | Sell | 7.2K | $41.93 |
| 2026-04-14 | Calvin Sandra | Sell | 22K | $41.07 |
| 2026-04-14 | Baynes Roy D. | Sell | 26K | $41.07 |
| 2026-04-14 | Heerma Peter | Sell | 7.2K | $41.93 |
| 2026-04-14 | Baynes Roy D. | Option exercise | 9.0K | $15.43 |
| 2026-04-14 | Calvin Sandra | Option exercise | 6.5K | $20.46 |
| 2026-04-14 | Calvin Sandra | Option exercise | 6.2K | $8.93 |
| 2026-04-14 | Calvin Sandra | Option exercise | 2.5K | $22.40 |
| 2026-04-13 | Dube Eric M | Grant | 64K | — |
| 2026-04-13 | Cline Christopher R. | Grant | 14K | — |
| 2026-04-13 | Cline Christopher R. | Sell | 65 | $28.85 |
| 2026-04-13 | Inrig Jula | Grant | 14K | — |
| 2026-04-13 | Heerma Peter | Grant | 14K | — |
| 2026-04-13 | ROTE WILLIAM E. | Grant | 14K | — |
| 2026-04-13 | REED ELIZABETH E | Grant | 14K | — |
| 2026-04-06 | Baynes Roy D. | Option exercise | 10K | $26.52 |
| 2026-04-06 | Baynes Roy D. | Sell | 10K | $33.00 |
| 2026-04-01 | Dube Eric M | Option exercise | 60K | $15.46 |
| 2026-04-01 | Dube Eric M | Sell | 35K | $30.55 |
| 2026-04-01 | Dube Eric M | Sell | 25K | $31.46 |
| 2026-04-01 | REED ELIZABETH E | Option exercise | 10K | $15.46 |
| 2026-04-01 | REED ELIZABETH E | Sell | 10K | $30.00 |
| 2026-03-16 | REED ELIZABETH E | Option exercise | 10K | $19.08 |
| 2026-03-16 | REED ELIZABETH E | Sell | 10K | $28.09 |
| 2026-02-20 | Dube Eric M | Sell | 60K | $30.10 |
| 2026-02-20 | Dube Eric M | Option exercise | 60K | $15.46 |
| 2026-02-17 | REED ELIZABETH E | Option exercise | 10K | $19.08 |
| 2026-02-17 | REED ELIZABETH E | Sell | 5.7K | $27.50 |
| 2026-02-17 | REED ELIZABETH E | Sell | 4.3K | $28.26 |
| 2026-02-04 | REED ELIZABETH E | Sell | 2.5K | $32.07 |
| 2026-02-04 | Inrig Jula | Sell | 232 | $32.85 |
| 2026-02-04 | Inrig Jula | Sell | 1.5K | $32.11 |
| 2026-02-04 | Cline Christopher R. | Sell | 110 | $32.90 |
| 2026-02-04 | Cline Christopher R. | Sell | 1.6K | $32.14 |
| 2026-02-04 | REED ELIZABETH E | Sell | 509 | $32.74 |
| 2026-02-03 | ROTE WILLIAM E. | Sell | 12K | $32.87 |
| 2026-02-03 | Cline Christopher R. | Sell | 7.2K | $32.12 |
| 2026-02-03 | Inrig Jula | Sell | 7.0K | $32.12 |
| 2026-02-03 | Calvin Sandra | Sell | 4.3K | $32.12 |
| 2026-02-03 | Heerma Peter | Sell | 7.3K | $32.12 |
| 2026-02-03 | Dube Eric M | Sell | 66K | $32.06 |
| 2026-02-03 | Dube Eric M | Sell | 34K | $32.70 |
| 2026-02-03 | REED ELIZABETH E | Sell | 7.2K | $32.12 |
| 2026-01-31 | ROTE WILLIAM E. | Grant | 20K | — |
| 2026-01-31 | Inrig Jula | Grant | 28K | — |
| 2026-01-31 | Dube Eric M | Grant | 114K | — |
| 2026-01-31 | Calvin Sandra | Grant | 15K | — |
| 2026-01-31 | Cline Christopher R. | Grant | 28K | — |
| 2026-01-31 | Heerma Peter | Grant | 26K | — |
| 2026-01-31 | REED ELIZABETH E | Grant | 25K | — |
| 2026-01-27 | Dube Eric M | Sell | 52K | $30.10 |
| 2026-01-27 | Dube Eric M | Option exercise | 52K | $15.46 |
| 2026-01-23 | Dube Eric M | Option exercise | 8.1K | $15.46 |
| 2026-01-23 | Dube Eric M | Sell | 8.1K | $30.01 |
| 2026-01-20 | REED ELIZABETH E | Option exercise | 10K | $19.08 |
| 2026-01-20 | REED ELIZABETH E | Sell | 10K | $27.34 |
| 2026-01-06 | Inrig Jula | Sell | 445 | $37.75 |
| 2026-01-05 | Inrig Jula | Sell | 2.0K | $40.18 |
| 2025-12-24 | Inrig Jula | Option exercise | 15K | $8.93 |
| 2025-12-24 | Inrig Jula | Sell | 15K | $42.00 |
| 2025-12-24 | Calvin Sandra | Sell | 7.4K | $40.00 |
| 2025-12-24 | Heerma Peter | Sell | 5.0K | $40.00 |
| 2025-12-24 | ROTE WILLIAM E. | Option exercise | 60K | $20.61 |
| 2025-12-24 | ROTE WILLIAM E. | Sell | 60K | $40.10 |
| 2025-12-15 | Calvin Sandra | Sell | 2.9K | $36.00 |
| 2025-12-01 | Cline Christopher R. | Option exercise | 20K | $16.23 |
| 2025-12-01 | Cline Christopher R. | Sell | 20K | $35.01 |
| 2025-11-04 | Calvin Sandra | Option exercise | 10K | $25.25 |
| 2025-11-04 | Calvin Sandra | Option exercise | 18K | $26.88 |
| 2025-11-04 | Calvin Sandra | Option exercise | 15K | $27.50 |
| 2025-11-04 | Calvin Sandra | Option exercise | 12K | $22.40 |
| 2025-11-04 | Calvin Sandra | Option exercise | 6.2K | $8.93 |
| 2025-11-04 | Calvin Sandra | Sell | 67K | $36.00 |
| 2025-11-03 | Heerma Peter | Gift | 1.1K | — |
| 2025-10-31 | Heerma Peter | Sell | 5.6K | $35.00 |
| 2025-10-31 | Coughlin Timothy | Option exercise | 8.0K | $16.33 |
| 2025-10-31 | Coughlin Timothy | Option exercise | 10K | $17.44 |
| 2025-10-31 | Coughlin Timothy | Sell | 18K | $35.03 |
| 2025-10-29 | Dube Eric M | Option exercise | 27K | $15.46 |
| 2025-10-29 | Dube Eric M | Sell | 27K | $30.12 |
| 2025-10-28 | Dube Eric M | Option exercise | 93K | $15.46 |
| 2025-10-28 | Heerma Peter | Sell | 2.7K | $30.00 |
| 2025-10-28 | Dube Eric M | Sell | 93K | $30.38 |
| 2025-09-23 | Heerma Peter | Gift | 891 | — |
| 2025-09-22 | REED ELIZABETH E | Option exercise | 10K | $19.08 |
| 2025-09-22 | REED ELIZABETH E | Sell | 10K | $25.00 |
| 2025-09-04 | Cline Christopher R. | Sell | 119 | $19.71 |
| 2025-09-03 | Cline Christopher R. | Sell | 454 | $18.20 |
| 2025-08-27 | Cline Christopher R. | Sell | 470 | $17.31 |
| 2025-07-01 | Inrig Jula | Sell | 815 | $14.65 |
| 2025-05-15 | Squarer Ron | Grant | 6.5K | — |
| 2025-05-15 | Williams Brinkley Ruth | Grant | 6.5K | — |
| 2025-05-15 | Poole Sandra | Grant | 6.5K | — |
| 2025-05-15 | Orwin John A | Grant | 6.5K | — |
| 2025-05-15 | Meckler Jeffrey A | Grant | 6.5K | — |
| 2025-05-15 | LYONS GARY A | Grant | 6.5K | — |
| 2025-05-15 | COUGHLIN TIMOTHY | Grant | 6.5K | — |
| 2025-05-15 | Bruhn Suzanne Louise | Grant | 6.5K | — |
| 2025-05-15 | Baynes Roy D. | Grant | 6.5K | — |
| 2025-05-05 | Heerma Peter | Sell | 1.8K | $21.05 |
| 2025-05-05 | Cline Christopher R. | Sell | 1.8K | $21.05 |
| 2025-05-05 | REED ELIZABETH E | Sell | 4.9K | $21.05 |
| 2025-05-05 | Dube Eric M | Sell | 19K | $21.05 |
| 2025-05-05 | ROTE WILLIAM E. | Sell | 3.2K | $21.05 |
| 2025-05-02 | Cline Christopher R. | Option exercise | 4.9K | — |
| 2025-05-02 | Dube Eric M | Option exercise | 19K | — |
| 2025-05-02 | Heerma Peter | Option exercise | 4.9K | — |
| 2025-05-02 | ROTE WILLIAM E. | Option exercise | 4.9K | — |
| 2025-05-02 | REED ELIZABETH E | Option exercise | 4.9K | — |
| 2025-04-11 | Cline Christopher R. | Sell | 48 | $13.14 |
| 2025-02-12 | Inrig Jula | Sell | 2.6K | $23.53 |
| 2025-02-12 | ROTE WILLIAM E. | Sell | 5.2K | $23.53 |
| 2025-02-12 | Heerma Peter | Sell | 2.6K | $23.53 |
| 2025-02-12 | REED ELIZABETH E | Sell | 8.0K | $23.53 |
| 2025-02-11 | Calvin Sandra | Option exercise | 10K | $17.96 |
| 2025-02-11 | Calvin Sandra | Sell | 10K | $25.00 |
| 2025-02-11 | Calvin Sandra | Sell | 15K | $25.00 |
| 2025-02-11 | Calvin Sandra | Sell | 9.2K | $25.00 |
| 2025-02-11 | Calvin Sandra | Option exercise | 15K | $15.46 |
| 2025-02-11 | Calvin Sandra | Option exercise | 10K | $16.23 |
| 2025-02-11 | Calvin Sandra | Sell | 10K | $25.00 |
| 2025-02-11 | Calvin Sandra | Option exercise | 10K | $17.44 |
| 2025-02-11 | Calvin Sandra | Sell | 10K | $25.00 |
| 2025-02-11 | Heerma Peter | Sell | 3.1K | $25.00 |
| 2025-02-11 | Dube Eric M | Sell | 11K | $24.04 |
| 2025-02-10 | ROTE WILLIAM E. | Option exercise | 8.0K | — |
| 2025-02-10 | Inrig Jula | Option exercise | 8.0K | — |
| 2025-02-10 | REED ELIZABETH E | Option exercise | 8.0K | — |
| 2025-02-10 | Heerma Peter | Option exercise | 8.0K | — |
| 2025-02-06 | Baynes Roy D. | Option exercise | 10K | $17.44 |
| 2025-02-06 | Baynes Roy D. | Sell | 10K | $22.00 |
| 2025-02-04 | Inrig Jula | Sell | 1.1K | $20.11 |
| 2025-02-03 | ROTE WILLIAM E. | Sell | 9.0K | $19.78 |
| 2025-02-03 | REED ELIZABETH E | Sell | 9.0K | $19.78 |
| 2025-02-03 | Dube Eric M | Sell | 51K | $20.21 |
| 2025-02-03 | Inrig Jula | Sell | 4.2K | $20.12 |
| 2025-02-03 | Heerma Peter | Sell | 5.2K | $20.12 |
| 2025-02-03 | Cline Christopher R. | Sell | 5.2K | $20.12 |
| 2025-02-03 | Calvin Sandra | Sell | 3.3K | $20.12 |
| 2025-01-31 | ROTE WILLIAM E. | Grant | 22K | — |
| 2025-01-31 | Heerma Peter | Grant | 22K | — |
| 2025-01-31 | Calvin Sandra | Grant | 13K | — |
| 2025-01-31 | REED ELIZABETH E | Grant | 22K | — |
| 2025-01-31 | Inrig Jula | Grant | 30K | — |
| 2025-01-31 | Dube Eric M | Grant | 130K | — |
| 2025-01-31 | Cline Christopher R. | Grant | 22K | — |
| 2025-01-23 | Baynes Roy D. | Option exercise | 16K | $17.50 |
| 2025-01-23 | Baynes Roy D. | Sell | 16K | $20.00 |
| 2025-01-22 | Dube Eric M | Sell | 11K | $19.46 |
| 2025-01-22 | Heerma Peter | Sell | 1.6K | $18.94 |
| 2025-01-22 | Calvin Sandra | Sell | 925 | $18.94 |
| 2025-01-22 | Cline Christopher R. | Sell | 865 | $18.94 |
| 2025-01-22 | ROTE WILLIAM E. | Sell | 2.4K | $19.46 |
| 2025-01-22 | REED ELIZABETH E | Sell | 2.4K | $19.46 |
| 2025-01-06 | Inrig Jula | Sell | 440 | $18.76 |
| 2025-01-03 | Inrig Jula | Sell | 2.1K | $19.10 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06431893 ↗ | A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) Homocystinuria | PHASE3 | Enrolling By Invitation | 2030-08-01 |
| NCT06247085 ↗ | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment Homocystinuria | PHASE3 | Recruiting | 2027-08-01 |
| NCT05003986 ↗ | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Focal Segmental Glomerulosclerosis, Minimal Change Disease | PHASE2 | Recruiting | 2027-03-12 |
| NCT07219121 ↗ | Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis Proteinuria, Immunoglobulin A (IgA) Nephropathy | PHASE4 | Active Not Recruiting | 2027-03-01 |
| NCT03406611 ↗ | Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE) Homocystinuria | PHASE1/PHASE2 | Active Not Recruiting | 2026-06-01 |
| NCT02998710 ↗ | Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA) Homocystinuria Due to CBS Deficiency | — | Recruiting | 2026-04-01 |
| NCT03762850 ↗ | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy Immunoglobulin A Nephropathy | PHASE3 | Active Not Recruiting | 2023-08-07 |
| NCT05856760 ↗ | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Immunoglobulin A Nephropathy | PHASE2 | Completed | 2024-10-14 |
| NCT05200871 ↗ | Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy | — | Completed | 2023-10-31 |
| NCT03493685 ↗ | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Focal Segmental Glomerulosclerosis | PHASE3 | Completed | 2023-03-20 |
| NCT02638220 ↗ | Cerebrotendinous Xanthomatosis (CTX) Prevalence Study Cerebrotendinous Xanthomatosis (CTX) | — | Completed | 2021-02-19 |
| NCT05562362 ↗ | Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension Healthy Subjects | PHASE1 | Completed | 2020-11-12 |
| NCT03041116 ↗ | Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants Pantothenate Kinase-Associated Neurodegeneration | PHASE3 | Terminated | 2019-12-30 |
| NCT01613118 ↗ | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis Focal Segmental Glomerulosclerosis | PHASE2 | Completed | 2016-06-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (0)
Suppliers (1)
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-16 | Exec/director change | filing ↗ |
| 2026-06-02 | Material agreementExhibits | filing ↗ |
| 2026-05-21 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-11 | Material agreementDebt obligation3.02OtherExhibits | filing ↗ |
| 2026-05-04 | ResultsExhibits | filing ↗ |
| 2026-04-14 | Other | filing ↗ |
| 2026-02-19 | ResultsExhibits | filing ↗ |
| 2026-01-13 | Other | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-16 | 2026-06-12 | 0001438533-26-000048 ↗ |
| 8-K | 2026-06-02 | 2026-06-01 | 0001193125-26-252474 ↗ |
| 8-K | 2026-05-21 | 2026-05-19 | 0001438533-26-000046 ↗ |
| 8-K | 2026-05-11 | 2026-05-06 | 0001193125-26-217100 ↗ |
| 10-Q | 2026-05-04 | 2026-03-31 | 0001438533-26-000042 ↗ |
| 8-K | 2026-05-04 | 2026-05-04 | 0001438533-26-000041 ↗ |
| 8-K | 2026-04-14 | 2026-04-13 | 0001438533-26-000032 ↗ |
| 10-K | 2026-02-19 | 2025-12-31 | 0001438533-26-000014 ↗ |
| 8-K | 2026-02-19 | 2026-02-19 | 0001438533-26-000013 ↗ |
| 8-K | 2026-01-13 | 2026-01-13 | 0001438533-26-000005 ↗ |
| 8-K | 2026-01-12 | 2026-01-12 | 0001438533-26-000003 ↗ |
| 10-Q | 2025-10-30 | 2025-09-30 | 0001438533-25-000056 ↗ |